key: cord-0051377-ulix5rpv authors: Shin, Daniel B.; Syed, Maha N.; Gelfand, Joel M. title: Commentary date: 2020-10-08 journal: J Am Acad Dermatol DOI: 10.1016/j.jaad.2020.10.001 sha: d97edd7ab31edfba6159ed75ec734ca9f53cf85c doc_id: 51377 cord_uid: ulix5rpv nan research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, 26 Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc, and he has received 27 payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and 28 Company and Ortho Dermatologics. In addition, Dr Gelfand is a copatent holder of resiquimod 29 for treatment of cutaneous T-cell lymphoma, and he is a deputy editor for the Journal of 30 Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. 31 Dr Syed is supported in part by a grant from Pfizer. Dr Shin has no disclosures to report. non-psoriasis populations introduces estimates that may be influenced by co-administration of 57 other immune suppressants or different underlying risk profile. Therefore, to yield a clinically 58 informative estimate, we believe researchers should only combine biologics with similar 59 indication (i.e. not combining psoriasis with Crohn's disease, ankylosing spondylitis, etc.). In 61 addition, non-approved therapies should be excluded from the primary analysis as their results 62 may be driven by doses that will not be approved. 63 64 Finally, the motivating factor behind our 3 meta-analyses is that we recognized that the analysis 65 of safety data on RTI were flawed as more than 10 adverse event (AE) terms are used to identify 66 this outcome in a safety dataset. Analyzing AEs individually can miss safety signals, making it 67 necessary to pool terms to investigate RTI. However, as we emphasized, evaluating the risk of 68 RTI in clinical trials is difficult because the diagnosis is made clinically without objective 69 testing, and therefore, the etiology of these symptoms, be they viral, bacterial, fungal, or allergic, 70 is unknown, and therefore we recommend specific testing for SARS-CoV-2 in ongoing and 71 future trials (Table 1 ). 2 Furthermore, meta-analysis of specific AEs depend on reporting 72 consistency, which is difficult due to threshold-dependent reporting criteria for publicly available 73 summaries. 74 The risk of respiratory tract infections and 85 interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune 86 diseases: a systematic review and meta-analysis The risk of respiratory tract infections and 88 symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate 89 of pivotal trials relevant to decision-making during the COVID-19 pandemic The Risk of Respiratory Tract 92 Psoriasis Patients Treated With IL-23-pathway Inhibiting Biologics: A Meta-93 Estimate of Pivotal Trials Relevant to Decision-Making During the COVID-19 Pandemic Effect of anti-tumor 96 necrosis factor therapy on the risk of respiratory tract infections and related symptoms in 97 psoriasis patients -A meta-estimate of pivotal phase 3 trials relevant to decision-making during 98 the COVID-19 pandemic Make SARS-CoV-2 testing available to trial subjects (For Sponsors/Investigators) COVID-19 is a highly variable illness with nonspecific symptoms. Systematic testing for SARS-CoV-2 in trial subjects presenting with RTI symptoms will allow for robust evaluation of drug safety.